TOP2A and prostate carcinoma: An avalanche of evidence has shown that TOP2A is overexpressed in various cancers, including HCC, malignant peripheral nerve sheath tumor, hepatoblastoma, breast cancer (BC), esophageal cancer, gastroesophageal cancer, pancreatic cancer, colorectal cancer (CRC), and prostate cancer (PCa) [6–9].